Key result
Antiplatelet agents targeting platelet adhesion, activation, and aggregation provide protection against thrombotic events, though balancing antithrombotic efficacy and bleeding risk remains a challenge.
This review provides a comprehensive overview of current and emerging antiplatelet therapies targeting different stages of thrombus formation.
Answers are grounded in this paper and cite their sources.
Requires individualized risk-benefit assessment in antiplatelet use; leaves open optimization of targeted therapies pending prospective trials.
Platelet adhesion, activation and aggregation to the injured vessel wall are crucially involved in the pathogenesis of thrombus formation. Agents in theory thwarting these phases would have significant clinical value. The current antiplatelet drugs used in daily clinical practice include COX-1 inhibitor aspirin, ADP P2Y 12 receptor antagonist clopidogrel, and the GPIIb-IIIa antagonists (abciximab, eptifibatide and tirofiban). However, confined curative ratio along with unforeseen bleeding risk remains a major puzzle of antiplatelet therapy. With advances in understanding of the molecular basis of platelet in thrombosis, newer antiplatelet agents that targets different stage of thrombus formation have been recently developed, mostly including agents targeting platelet adhesion (GPIV, vWF), activation (GPVI, P2Y 12 , TP, PAR1, phosphodiesterase, cyclooxygenase), and aggregation (GPIIb/IIIa). In this article, we will review the advantages and limitations of various antiplatelet agents that have been approved by the US Food and Drug Administration (FDA) or under development.
No takes yet. Share an insight, caveat, or question.
Jing Fang (2013) conducted a review in Thrombosis and thromboembolic disorders. Antiplatelet agents was evaluated. Antiplatelet agents targeting platelet adhesion, activation, and aggregation provide protection against thrombotic events, though balancing antithrombotic efficacy and bleeding risk remains a challenge.
Synapse has enriched 10 related papers. Consider them for comparative context: